PMID- 29750764
OWN - NLM
STAT- MEDLINE
DCOM- 20200313
LR  - 20200313
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Linking)
VI  - 38
IP  - 3
DP  - 2019 Mar
TI  - Linezolid-containing Treatment Regimens for Tuberculosis in Children.
PG  - 263-267
LID - 10.1097/INF.0000000000002093 [doi]
AB  - BACKGROUND: In recent years, there is an increasing interest in the use of 
      linezolid for the treatment of tuberculosis (TB). METHODS: Patients less than 18 
      years of age who received linezolid within the Spanish Pediatric TB Network from 
      2001 to 2016 were retrospectively included. Treatment characteristics, adverse 
      events (AEs) and outcomes were analyzed. RESULTS: Fifteen children were included 
      (53% male) with a median age of 3.6 years [interquartile range (IQR): 1.6-6.2]. 
      Median follow-up was 54 months (IQR: 38-76). The reasons for linezolid use were 
      drug-resistant TB in 8 (53%) patients, drug-induced liver injury in 5 (33%) 
      patients and chronic liver disease in 2 (13%) patients. Four children (26%) were 
      on immunosuppressive therapy when TB was diagnosed. Five children (33%) were 
      diagnosed with extrapulmonary TB. The median duration of linezolid treatment was 
      13 months (IQR: 7.5-17). Nine patients had 13 linezolid-related AEs. Hematologic 
      toxicity was observed in 8 patients (53%) and gastrointestinal intolerance in 3 
      patients (20%). In 2 patients, linezolid dose was reduced, and in 2 patients, 
      linezolid was discontinued because of AEs. A 2-year-old girl went back to her 
      country of birth and was lost to follow-up. No relapses were observed among the 
      other 14 patients (93%). CONCLUSIONS: Linezolid may be considered when treating 
      children with drug-resistant TB but also in the cases of patients with chronic 
      liver disease or drug-induced liver injury. However, AEs should be closely 
      monitored. Further studies are needed to determine the optimum dosage and the 
      optimal duration of linezolid treatment in children.
FAU - Prieto, Luis M
AU  - Prieto LM
AD  - From the Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital 
      Universitario 12 de Octubre, Madrid, Spain.
FAU - Santiago, Begona
AU  - Santiago B
AD  - Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital General 
      Universitario Gregorio Maranon, Madrid, Spain.
FAU - Del Rosal, Teresa
AU  - Del Rosal T
AD  - Tropical and Infectious Diseases Unit, Department of Paediatrics, Hospital 
      Universitario La Paz, Madrid, Spain.
FAU - Carazo, Begona
AU  - Carazo B
AD  - Pediatric Infectious Diseases and Immunodeficiencies Unit, Department of 
      Paediatrics, Hospital Regional Universitario de Malaga, Malaga, Spain.
FAU - Jimenez, Ana B
AU  - Jimenez AB
AD  - Department of Paediatrics, Hospital Universitario Fundacion Jimenez Diaz, Madrid, 
      Spain.
FAU - Perez-Gorricho, Beatriz
AU  - Perez-Gorricho B
AD  - Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Infantil 
      Universitario Nino Jesus, Madrid, Spain.
FAU - Rubio, Felipe
AU  - Rubio F
AD  - Department of Paediatrics, Hospital Nuestra Senora de Sonsoles, Avila, Spain.
FAU - Tagarro, Alfredo
AU  - Tagarro A
AD  - Department of Paediatrics, Hospital Universitario Infanta Sofia, San Sebastian de 
      los Reyes, Spain.
FAU - Blazquez-Gamero, Daniel
AU  - Blazquez-Gamero D
AD  - From the Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital 
      Universitario 12 de Octubre, Madrid, Spain.
FAU - Moreno-Perez, David
AU  - Moreno-Perez D
AD  - Pediatric Infectious Diseases and Immunodeficiencies Unit, Department of 
      Paediatrics, Hospital Regional Universitario de Malaga, Malaga, Spain.
FAU - Mellado, Maria J
AU  - Mellado MJ
AD  - Tropical and Infectious Diseases Unit, Department of Paediatrics, Hospital 
      Universitario La Paz, Madrid, Spain.
FAU - Baquero-Artigao, Fernando
AU  - Baquero-Artigao F
AD  - Tropical and Infectious Diseases Unit, Department of Paediatrics, Hospital 
      Universitario La Paz, Madrid, Spain.
CN  - Spanish Paediatric TB Research Network (pTBred)
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Antitubercular Agents)
RN  - ISQ9I6J12J (Linezolid)
SB  - IM
MH  - Adolescent
MH  - Antitubercular Agents/adverse effects/*therapeutic use
MH  - Chemical and Drug Induced Liver Injury
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Linezolid/adverse effects/*therapeutic use
MH  - Male
MH  - Retrospective Studies
MH  - Spain
MH  - Treatment Outcome
MH  - Tuberculosis, Multidrug-Resistant/*drug therapy
EDAT- 2018/05/12 06:00
MHDA- 2020/03/14 06:00
CRDT- 2018/05/12 06:00
PHST- 2018/05/12 06:00 [pubmed]
PHST- 2020/03/14 06:00 [medline]
PHST- 2018/05/12 06:00 [entrez]
AID - 10.1097/INF.0000000000002093 [doi]
PST - ppublish
SO  - Pediatr Infect Dis J. 2019 Mar;38(3):263-267. doi: 10.1097/INF.0000000000002093.